| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01774578 Details | 2020-05-28 Interventional | 2/3 | 135 | Docetaxel Gemcitabine Pemetrexed Carcinoma, Non-… Lung Neoplasms Non-small Cell … Non-small Cell … Progression of … | - - | |||
| NCT00614601 Details | 2020-05-28 Interventional | 2 | 9 | Vaccines Pancreatic Neop… Pancreatic Canc… | Sponsor proceeded with a phase III study for same indication. - | |||
| NCT03565406 Details | 2020-05-21 Interventional | 1 | 11 | Ipilimumab Mocetinostat Nivolumab Melanoma | recruiting or enrolling participants has halted prematurely and will not resume; participants
are no longer being examined or treated - | |||
| NCT03361228 Details | 2020-05-21 Interventional | 1/2 | 5 | Pembrolizumab Neoplasms Solid Tumors | Study was terminated early based on emerging data with epacadostat and pembrolizumab. - | |||
| NCT02321319 Details | 2020-05-21 Interventional | 3 | 5 | Hydromorphone Chronic Pain | Business decision - product discontinued - | |||
| NCT03580382 Details | 2020-05-20 Interventional | 1/2 | 3 | Antibodies Trametinib Melanoma | Per regulatory coordinator, the sponsor is no longer supporting the study. - | |||
| NCT03506620 Details | 2020-05-20 Interventional | 4 | 0 | Ropivacaine Femoracetabular… Femoroacetabula… | Unforeseen cost restrictions of the drug halted the execution of this study altogether. - | |||
| NCT02017600 Details | 2020-05-20 Interventional | 2 | 48 | Fluorouracil Carcinoma Carcinoma, Squa… Esophageal Neop… Esophageal Squa… Localized Squam… | - - | |||
| NCT04066790 Details | 2020-05-19 Interventional | 2 | 12 | Paclitaxel Trastuzumab Breast Neoplasm… Breast Cancer | We terminated this trial and initiated a new one including pertuzumab. - | |||
| NCT03150420 Details | 2020-05-19 Interventional | 3 | 29 | Sodium thiosulf… Calciphylaxis | Inability to accrue subjects that met the exclusion criterion "Any prior (within the past 30
days) or current Sodium Thiosulfate treatment". - | |||
| NCT02624986 2015-002100-83 Details | 2020-05-18 Interventional | 1/2 | 25 | Obinutuzumab Rituximab Lymphoma Lymphoma, Folli… Lymphoma, Large… Non-Hodgkin's L… | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. Due to the overall modest benefit achieved with the maximum tolerated dose during the dose escalation phase, the Sponsor decided not to open the expansion phase and terminated the study. Consequently, some planned analyses could not be performed. | |||
| NCT02909257 Details | 2020-05-14 Interventional | 4 | [10 Refs] | 31 | Bupivacaine Knee Injuries Osteoarthritis,… | inadequate methodology to determine primary outcome - | ||
| NCT01570361 Details | 2020-05-14 Interventional | 4 | 255 | Anti-Arrhythmia… Atrial Fibrilla… | The sponsor decided to terminate the study early due to enrolment not proceeding in accordance
with expectations, independently from the study outcome. As the study was terminated early without having met primary effectiveness or futility criteria, the study results should be interpreted with caution. | |||
| NCT01318590 Details | 2020-05-13 Interventional | 3 | 2 | Bupivacaine Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Pancreatitis Pancreatitis, C… | Closed by CHUM REB for incomplete documentation of research activities. - | |||
| NCT02282904 Details | 2020-05-12 Interventional | 1/2 | 7 | Busulfan Cyclophosphamid… Fludarabine Sirolimus Granuloma Granulomatous D… Chronic Granulo… | - - | |||
| NCT00303719 Details | 2020-05-12 Interventional | 2 | 342 | Antilymphocyte … Cyclophosphamid… Cyclosporine Cyclosporins Fludarabine Mycophenolic Ac… Kidney Neoplasm… Multiple Myelom… Myelodysplastic… Neoplasms, Plas… Plasmacytoma Kidney Cancer Leukemia Lymphoma Plasma Cell Neo… | IRB Study Closure - | |||
| NCT02906696 Details | 2020-05-11 Interventional | 2 | 8 | Bosutinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Blasts Under 15… Blasts Under 15… Blasts Under 30… Blasts Under 30… Chronic Phase C… | Terminated per PI's request due to competing priorities. - | |||
| NCT03053063 2016-004148-13 Details | 2020-05-07 Interventional | 3 | [8 Refs] | 883 | Selonsertib Fatty Liver Non-alcoholic F… Nonalcoholic St… | This study was terminated early due to lack of efficacy based on the results of the Week 48
analysis as prespecified in the clinical study protocol. Based on the results of the Week 48 analysis, the study was terminated early for lack of efficacy as prespecified in the clinical study protocol. | ||
| NCT02061774 Details | 2020-05-06 Interventional | 4 | 21 | Acetaminophen Low Back Pain | Preliminary analysis showed not clinically significant. Study ended and closed 1/11/2018 Early Termination due to preliminary analysis showed not clinically significant | |||
| NCT02385669 Details | 2020-05-05 Interventional | 1/2 | 3 | Ipilimumab Melanoma | why study stopped - |